|
| |
| We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery. This field, covering as it does both structure-based drug design, high-content drug screening and structure-guided, property-based lead optimization, is one of the most important and exciting areas in drug discovery today. This Resource Centre aims to introduce new researchers to, and update existing researchers in, the field of fragment-based drug discovery. Welcome to the world of fragment-based drug discovery! |
| |
|
|
| |
| Within the space of only a few years, fragment-based drug design (FBDD) has emerged as an efficient and productive route for de novo drug discovery. Using tailored sets of chemical fragments (see IOTA Libraries) FBDD is delivering high-quality drug leads against a multiplicity of new therapeutic targets in the pharmaceutical sector. | | | | FBDD also offers the prospect of rapid hypothesis testing and validation of recently discovered molecular targets for use in drug discovery, of particular relevance for start-up biotechnology companies eager to add a new dimension to their discovery offerings. | | | | In this overview of the FBDD approach, IOTA co-founders Dr Bailey and Dr Boyd review FBDD and its role in design-led discovery biology. |
|
| |
|
|
| |
| IOTA is assembling a comprehensive FBDD literature resource as a service to scientists working in the FBDD area. The first draft of this is attached. |
| |
| If you have published a paper in the FBDD area which should be included in this list and does not currently appear, please send an email to info@iotapharma.com and we will include it. |
| |
| |
|
|
| |
| A growing number of proteins have been published as targets for FBDD studies. An updated list can be found in the attached document. | | | | If you have published a paper on design to a target using FBDD that is not currently on this list, please let IOTA know by emailing us at info@iotapharma.com, and we will include it. |
|
| |
|
|
| |
| Several academic laboratories are now working in the FBDD area, some focussing on FBDD as a design tool, others integrating it into their drug discovery platforms. These are listed in the attached document. | | | | If you are currently working with FBDD and are not included in this list, contact us at info@iotapharma.com |
|
| |
